Review suggests treating diabetic foot disease with distant therapies

KNOXVILLE, TN, September 05, 2026 /CourierPR/ -- A team of researchers from the University of New Mexico School of Medicine, Pasadena City College, the Keck School of Medicine of USC, Rancho Los Amigos National Rehabilitation Center, the University of California, Los Angeles, and Chongqing University Central Hospital has published a review in the journal Burns & Trauma, suggesting that treating diabetic foot disease may not be limited to the affected area. The study proposes that carefully delivered signals at one site can improve circulation, reduce inflammation, and promote tissue repair at another, potentially shifting care from local rescue to biologically restorative strategies.

Diabetic foot ulcers (DFUs) develop due to a combination of neuropathy, poor blood supply, inflammation, infection, and impaired healing. Chronic limb-threatening ischemia (CLTI) exacerbates the risk of tissue loss, amputation, cardiovascular events, and death. While standard wound care, glucose control, debridement, and revascularization remain essential, many ulcers heal slowly, recur after closure, or occur in patients who cannot undergo further vascular procedures.

The review, published on April 8, 2026, explores emerging strategies that could offer scalable options for limb preservation. The researchers examined neuromodulatory, humoral, and mechanotransductive interventions, which may produce benefits far from their application site. These approaches include high-frequency spinal cord stimulation (SCS), peripheral focused ultrasound (pFUS), remote ischemic conditioning (RIC), and surgical procedures like tibial transverse transport (TTT) and lateral tibial periosteum distraction (LTPD).

High-frequency SCS, delivered at 10 kilohertz, directly alters neural signaling and sympathetic activity. In a randomized trial of refractory painful diabetic neuropathy, 79% of patients receiving SCS plus conventional medical management achieved the main pain-and-neurological endpoint, compared to only 5% receiving medical management alone. Neurological improvement was reported in 62% of SCS recipients versus 3% in the control group at six months.

Peripheral focused ultrasound (pFUS), including splenic targeting, may engage neuroimmune reflexes and reduce inflammatory cytokines. While much of the wound-healing evidence remains preclinical or early-phase, early studies show promise. One small diabetic-foot study reported higher healing rates, including 41% complete healing compared to none with placebo, and 75.6% versus 36.6% by week 20 in another study.

Remote ischemic conditioning (RIC) uses brief cycles of limb ischemia and reperfusion to release circulating protective mediators and improve endothelial function. Small diabetic-foot studies showed higher healing rates, with one trial reporting 41% complete healing versus none with placebo and another study showing 75.6% versus 36.6% by week 20.

Surgical approaches such as TTT and LTPD apply controlled mechanical tension to stimulate angiogenesis and distal perfusion. Proposed pathways include osteopontin (OPN), stromal interaction molecule 1 (STIM1), endothelial nitric oxide synthase (eNOS), and nitric oxide (NO) signaling, though clinical evidence remains geographically concentrated and methodologically uneven.

The authors emphasized that a diabetic foot ulcer should be viewed as the visible result of disrupted neural, vascular, and immune systems. Interventions delivered through the spinal cord, spleen, another limb, or the tibial periosteum may help recreate the biological conditions needed for healing at a distant site. However, they stressed that encouraging early signals should not be mistaken for definitive proof, as many studies remain small, heterogeneous, short-term, or dependent on preclinical models and specialized surgical centers.

The emerging framework could eventually give clinicians more options for patients with refractory neuropathic pain, non-healing ulcers, or limited revascularization choices. Non-invasive approaches such as pFUS and RIC may be especially attractive where surgery or implantable devices are impractical, while SCS and periosteal procedures may serve carefully selected patients in specialist centers.

Before broad adoption, researchers need adequately powered multicenter randomized controlled trials (RCTs) to measure amputation-free survival, ulcer recurrence, sustained perfusion, function, and quality of life over at least 12 to 24 months. Standardized dosing, patient-selection rules, safety registries, cost-effectiveness analyses, and equitable access will be essential to determine whether "action at a distance" can become dependable limb-preservation care.